View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Jun. 30, 2014
Amendment flag	false
Document Period Focus	Q2
Document Fiscal Year Focus	2014
Current fiscal year end date	--06-14
Entity central index key	0001123494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity voluntary filers	No
Entity well known seasoned issuer	No
Entity common stock shares outstanding		32,296,691

Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 26,434	$ 25,771
Accounts receivable, net of allowance for doubtful accounts of $328 and $358, respectively	14,308	13,884
Inventories	17,211	15,777
Deferred income tax assets - current	1,545	1,547
Assets Held For Sale Current	331	0
Other receivables and other assets	4,562	3,771
Total current assets	64,391	60,750
Property, plant and equipment, net	4,128	4,375
Deferred income tax assets - non-current	13,006	13,116
Amortizable intangible assets, net	17,679	19,009
Goodwill	36,839	36,605
Other indefinite lived intangible assets	1,287	1,289
Other assets	378	316
Total Assets	137,708	135,460
Current liabilities:
Current portion, long-term debt	5,000	5,000
Accounts payable	5,060	4,682
Deferred revenue	609	640
Accrued income taxes payable	72	99
Accrued expenses	4,620	5,078
Other liabilities - current	1,004	586
Total current liabilities	16,365	16,085
Long-term debt	17,250	19,750
Deferred income tax liabilities - non-current	139	160
Other liabilities- non current	5,728	4,980
Total liabilities	39,482	40,975
Commitments and contingencies	0	0
Stockholders Equity Abstract
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 39,981,918 and 39,384,974 shares issued and 32,236,411 and 31,639,467 shares outstanding, respectively	394	390
Additional paid-in-capital	204,353	202,446
Accumulated deficit	(93,298)	(95,039)
Accumulated other comprehensive loss	(2,555)	(2,644)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	98,226	94,485
Total liabilities and stockholders' equity	$ 137,708	$ 135,460

Statements of Financial Position (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 328	$ 358
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	39,981,918	39,384,974
Common Stock- Shares Outstanding	32,236,411	31,639,467
Treasury Stock common shares	7,745,507	7,745,507

Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)
Revenues	$ 26,958	$ 26,094	$ 52,851	$ 52,181
Cost of product revenues (exclusive of items shown separately below)	14,680	14,005	28,812	27,831
Gross profit	12,278	12,089	24,039	24,350
Sales and marketing expenses	4,557	4,393	8,989	8,932
General and administrative expenses	3,997	4,359	8,248	8,581
Research and development expenses	1,284	922	2,257	1,935
HART transaction costs	0	1,016	0	1,520
Restructuring charges (credits)	115	(24)	252	(45)
Amortization of intangible assets	587	676	1,221	1,355
Total Operating Expenses	10,540	11,342	20,967	22,278
Operating income	1,738	747	3,072	2,072
Other (expense) income:
Foreign exchange	(67)	(25)	(148)	9
Interest expense	(248)	(245)	(513)	(374)
Interest income	12	10	26	19
Other income (expense), net	(165)	(69)	(148)	(81)
Other expense, net	(468)	(329)	(783)	(427)
Income from continuing operations before income taxes	1,270	418	2,289	1,645
Total Income Tax Expense	248	322	548	620
Income from continuing operations	1,022	96	1,741	1,025
Discontinued Operations [Abstract]
Loss from Discontinued Operations, Net of Tax, Attributable to Parent	0	(282)	0	(1,117)
Net income (loss)	$ 1,022	$ (186)	$ 1,741	$ (92)
Earnings (loss) per share:
Basic earnings per common share from continuing operations	$ 0.03	$ 0.00	$ 0.05	$ 0.03
Discontinued operations	0	(0.01)	0	(0.03)
Basic earnings per common share	0.03	(0.01)	0.05	0.00
Diluted earnings per common share from continuing operations	0.03	0.00	0.05	0.03
Discontinued operations	0	(0.01)	0	(0.03)
Diluted Earnings Per Common Share	$ 0.03	$ (0.01)	$ 0.05	$ 0.00
Weighted average common shares:
Basic	32,045,314	30,102,691	31,946,654	29,941,294
Diluted	32,945,932	31,695,238	32,935,455	31,680,264
Comprehensive Income Net Of Tax [Abstract]
Net income (loss)	$ 1,022	$ (186)	$ 1,741	$ (92)
Unrealized losses on pension benefit obligation, net of tax	(484)	0	(484)	0
Foreign currency translation adjustments	369	193	584	(1,844)
Other Comprehensive Income Derivatives Qualifying As Hedges Net Of Tax Period Increase Decrease [Abstract]
Loss on derivative instruments designated and qualifying as cash flow hedges	(56)	(53)	(80)	(53)
Amounts reclassified from accumulated other comprehensive income to net income	34	7	69	7
Total Comprehensive Income (Loss), Net of Tax, total	$ 885	$ (39)	$ 1,830	$ (1,982)

Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income (loss)	$ 1,741	$ (92)
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	919	1,237
Depreciation	608	662
Receivable for the earn-out related to discontinued assets	0	339
(Gain) loss on sales of fixed assets	(4)	1
Non cash restructuring charge	(118)	(44)
Amortization Of Catalog Costs	24	56
Provision for allowance for doubtful accounts	(30)	42
Amortization of intangible assets	1,221	1,355
Amortization of deferred financing costs	30	15
Deferrred Income Taxes	119	(1,301)
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(294)	265
Increase in inventories	(1,312)	(932)
Increase in other receivables and other assets	(864)	(773)
Increase in trade accounts payable	349	287
(Decrease) increase in accrued income taxes	(7)	396
Increase in accrued expenses	51	281
(Decrease) increase in deferred revenue	(36)	267
Increase (decrease) in other liabilities	89	(3)
Net cash provided by operating activities	2,486	1,380
Cash flows (used in) provided by investing activities:
Additions to property, plant and equipment	(744)	(585)
Additions to catalog costs		(57)
Proceeds from sales of property, plant and equipment	78	3
Net cash used in investing activities	(666)	(639)
Cash flows provided by (used in) financing activities:
Repayments of debt	(2,500)	(750)
Net proceeds from issuance of debt	0	12,049
Net proceeds from issuance of common stock	1,001	1,999
Net cash (used in) provided by financing activities	(1,499)	13,298
Effect of exchange rate changes on cash	342	(622)
Increase in cash and cash equivalents	663	13,417
Cash and cash equivalents at the begining of period	25,771	20,681
Cash and cash equivalents at the end of period	26,434	34,098
Supplemental disclosures of cash flow information [Abstract]
Cash paid for interest	458	272
Cash paid for income taxes, net of refunds	$ 688	$ 1,006

Basis of Presentation and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2014

Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]

HARVARD BIOSCIENCE, INC.

Notes to Unaudited Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of June 30, 2014 and for the three and six months ended June 30, 2014 and 2013 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2013 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 14, 2014.

In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2014, results of operations and comprehensive income (loss) for the three and six months ended June 30, 2014 and 2013 and cash flows for the six months ended June 30, 2014 and 2013, as applicable, have been made. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Summary of Significant Accounting Policies

The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 14, 2014.

Recently Issued Accounting Pronouncements

6 Months Ended

Jun. 30, 2014

Recently Issued Accounting Pronouncements [Abstract]

Recently Issued Accounting Pronouncements Disclosure [Text Block]

2. Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. This standard will be effective as of the beginning of the Company's 2017 fiscal year. The Company is assessing the new standard and has not yet determined the impact to the consolidated financial statements.

Accumulated Other Comprehensive Income

6 Months Ended

Jun. 30, 2014

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income Disclosure [Text Block]

3. Accumulated Other Comprehensive (Loss) Income

Changes in each component of accumulated other comprehensive (loss) income, net of tax are as follows:

		Foreign currency		Derivatives
		translation		qualifying as		Defined benefit
(in thousands)		adjustments		hedges		pension plans		Total

Balance at December 31, 2013	$	1,283	$	(49)	$	(3,878)	$	(2,644)

Other comprehensive income (loss) before reclassifications		584		(80)		(484)		20
Amounts reclassified from AOCI		-		69		-		69

Net other comprehensive income		584		(11)		(484)		89

Balance at June 30, 2014	$	1,867	$	(60)	$	(4,362)	$	(2,555)

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2014

Goodwill And Other Intangible Assets Disclosure [Abstract]

Goodwill And Other Intangible Assets Disclosure [Text Block]

4. Goodwill and Other Intangible Assets

Intangible assets consist of the following:

									Weighted
									Average
		June 30, 2014				December 31, 2013			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	13,581	$	(11,480)	$	13,464	$	(11,091)	3.9	Years
Trade names		6,141		(2,374)		6,178		(2,185)	10.5	Years
Distribution agreement/customer relationships		21,713		(10,155)		21,827		(9,447)	10.2	Years
Patents		280		(27)		271		(8)	4.7	Years
Total amortizable intangible assets		41,715	$	(24,036)		41,740	$	(22,731)

Indefinite-lived intangible assets:
Goodwill		36,839				36,605
Other indefinite-lived intangible assets		1,287				1,289
Total goodwill and other indefinite-lived intangible assets		38,126				37,894

Total intangible assets	$	79,841			$	79,634

(a) Weighted average life as of June 30, 2014.

The change in the carrying amount of goodwill for the six months ended June 30, 2014 is as follows:

			(in thousands)
Balance at December 31, 2013		$	36,605
	Effect of change in foreign currencies		234
Balance at June 30, 2014		$	36,839

Intangible asset amortization expense was $0.6 million and $0.7 million for the three months ended June 30, 2014 and 2013, respectively. Intangible asset amortization expense was $1.2 million and $1.4 million for the six months ended June 30, 2014 and 2013, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $2.5 million for the year ending December 31, 2014, $2.2 million for the year ending December 31, 2015, $2.1 million for the year ending December 31, 2016, $1.8 million for the year ending December 31, 2017 and $1.7 million for the year ending December 31, 2018.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Inventories

6 Months Ended

Jun. 30, 2014

Inventories Disclosure [Abstract]

Inventories Disclosure [Text Block]

5. Inventories

Inventories consist of the following:

			June 30,		December 31,
			2014		2013
			(in thousands)
Finished goods		$	8,396	$	7,039
Work in process			663		752
Raw materials			8,152		7,986
	Total	$	17,211	$	15,777

Property, Plant and Equipment

6 Months Ended

Jun. 30, 2014

Property, Plant and Equipment Disclosure [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

6. Property, Plant and Equipment

Property, plant and equipment consist of the following:

		June 30,		December 31,
		2014		2013
		(in thousands)
Land, buildings and leasehold improvements	$	2,446	$	3,082
Machinery and equipment		9,994		9,471
Computer equipment and software		5,298		4,927
Furniture and fixtures		1,336		1,281
Automobiles		59		59
		19,133		18,820
Less: accumulated depreciation		(15,005)		(14,445)
Property, plant and equipment, net	$	4,128	$	4,375

Restructuring and Other Exit Costs

6 Months Ended

Jun. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring And Other Exit Costs Disclosure [Text Block]

7. Restructuring and Other Exit Costs

2013 Restructuring Plan

During the fourth quarter of 2013, the management of Harvard Bioscience initiated a plan to realign global operations to improve organizational efficiencies and reduce operating expenses throughout the Company. The plan included an approximately 13% reduction in the workforce, as well as the elimination of the position of Chief Operating Officer. During 2013, the Company recorded restructuring charges of approximately $2.1 million representing severance payments. Additional charges related to this plan are expected to be incurred through the third quarter of 2014, and include, but are not limited to, contract termination costs, as well as moving and employee relocation costs. For the three and six months ended June 30, 2014, the Company recorded net restructuring charges of approximately $0.1 million and $0.3 million, respectively, representing severance and other payments. Payments related to this plan are expected to be made through the end of 2014. Activity and liability balances related to these charges were as follows:

		Severance and
		Related Costs		Other		Total
		(in thousands)
Restructuring charges - 2013	$	2,100	$	-	$	2,100
Cash payments		(666)		-		(666)
Restructuring balance at December 31, 2013		1,434		-		1,434
Restructuring charges		195		175		370
Non-cash reversal of restructuring charges		(115)		-		(115)
Cash payments		(1,184)		(159)		(1,343)
Restructuring balance at June 30, 2014	$	330	$	16	$	346

As part of the 2013 Restructuring Plan, the Company decided to close one of its facilities in the United Kingdom. As of June 30, 2014, the facility met the criteria to be classified as an asset held-for-sale under Accounting Standards Codification (ASC 360), Property, Plant, and Equipment. The facility has been included as a current asset, at its net book value at the time it was classified as held-for-sale, in the consolidated balance sheet as it is anticipated the facility will be sold within one year of the balance sheet date.

2012 Restructuring Plan

During 2012, the management of Harvard Bioscience initiated a plan to reduce operating expenses at one of its foreign subsidiaries. The Company recorded restructuring charges of approximately $0.3 million representing severance payments. No further charges are expected to be incurred on this matter. As of June 30, 2014, the Company had no remaining liability related to this plan on its balance sheet. Activity and liability balances related to these charges were as follows:

		Severance
		and Related Costs		Other		Total
		(in thousands)
Restructuring charges	$	312	$	11	$	323
Cash payments		(179)		-		(179)
Restructuring balance at December 31, 2012		133		11		144
Cash payments		(84)		(11)		(95)
Non-cash reversal of restructuring charges		(46)		-		(46)
Restructuring balance at December 31, 2013		3		-		3
Non-cash reversal of restructuring charges		(3)		-		(3)
Restructuring balance at June 30, 2014	$	-	$	-	$	-

Aggregate net restructuring charges relating to the 2013 Restructuring Plan and the 2012 Restructuring Plan were as follows:

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)				(in thousands)
Restructuring charges (credits)	$	115	$	(24)	$	252	$	(45)

Discontinued Operations

6 Months Ended

Jun. 30, 2014

Discontinued Operations [Abstract]

Discontinued Operations Disclosure [Text Block]

8. Discontinued Operations

UBI

In September 2008, the Company completed the sale of assets of its Union Biometrica Division (“UBI”) including its German subsidiary, Union Biometrica GmbH, to UBIO Acquisition Company. During 2013, the Company received earn-out payments, including interest, from UBIO Acquisition Company, of $1.8 million related to the 2008 acquisition. The Company received its final payment under the earn-out obligation from UBIO Acquisition Company in October 2013.

HART

On November 1, 2013, the spin-off of Harvard Apparatus Regenerative Technology, Inc., or HART, from the Company was completed. Through the spin-off date, the historical operations of HART were reported as continuing operations in the consolidated statements of operations of the Company. Following the spin-off, the historical operations of HART have been reclassified and reported as discontinued operations for all periods presented. As a result of the spin-off and related separation, HART became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience's stockholders of record all of the shares of common stock of HART (the “Distribution”). In the Distribution, the Company distributed to its stockholders one share of HART common stock for every four shares of Harvard Bioscience common stock outstanding as of the close of business on October 21, 2013, the record date for the Distribution. Fractional shares of HART common stock were not included in the distribution. Instead, Registrar & Transfer Company aggregated fractional shares into whole shares, sold the whole shares in the open market and distributed the aggregate net cash proceeds of the sales pro rata to each holder who otherwise would have been entitled to receive a fractional share in the Distribution.

Effective with the spin-off, the Company contributed $15.0 million in cash to HART to fund its operations. In addition, the Company transferred approximately $0.9 million in assets, made up primarily of property, plant and equipment, to HART as part of the spin-off.

In connection with the spin-off of HART, certain required adjustments were made to the Company's outstanding equity compensation awards under its employee benefit plans. Each outstanding option to purchase Harvard Bioscience common stock was converted on the date of the Distribution into both an adjusted Harvard Bioscience option to purchase Harvard Bioscience common stock and an option to purchase HART common stock. Black-Scholes valuation modeling was used to determine the value that each Harvard Bioscience option had lost at the time of the Distribution and to ensure the holder maintained such lost value, 80% of such lost value was provided back to the holder by making appropriate adjustments to the share amount and exercise price of the existing Harvard Bioscience option and 20% of such lost value was provided back to the holder through the issuance of an option to purchase HART common stock. Similar to the adjustment of the existing Harvard Bioscience options, with respect to each unvested Harvard Bioscience restricted stock unit outstanding at the time of the Distribution, such Harvard Bioscience restricted stock unit was converted on the date of the Distribution into both an adjusted Harvard Bioscience restricted stock unit and a HART restricted stock unit. The market prices of Harvard Bioscience and HART common stock were used to determine the value that each Harvard Bioscience restricted stock unit lost at the time of the Distribution and then to ensure the holder maintained such lost value, 80% of such lost value was provided back to the holder by making the appropriate increases of the share amount of the existing Harvard Bioscience restricted stock unit and 20% of such lost value was provided back to the holder through the issuance of a HART restricted stock unit. The share amounts and exercise prices of the adjusted Harvard Bioscience options and HART options, as well as the share amounts of the adjusted Harvard Bioscience restricted stock units and HART restricted stock units, were each adjusted and set in a manner to ensure the intrinsic value held by the holder pertaining to the existing Harvard Bioscience award was maintained immediately following the Distribution and was determined such that tax was not triggered under Section 409A of the Internal Revenue Code. As part of these required adjustments, the Company issued approximately 1.7 million options and approximately 0.1 million restricted stock units to holders of its outstanding equity compensation awards.

In connection with the spin-off, on October 31, 2013, the Company entered into various commercial agreements with HART which contain many of the key terms, conditions and arrangements related to the Distribution. A description of certain of these agreements can be found in Note 9.

Harvard Bioscience intends for the Distribution and related separation, taken together, to qualify as a reorganization pursuant to which no gain or loss is recognized by Harvard Bioscience or its stockholders for federal income tax purposes under Sections 355, 368(a)(1)(D) and related provisions of the Internal Revenue Code. On June 28, 2013, Harvard Bioscience received a Supplemental Ruling to the Private Letter Ruling dated March 22, 2013 from the IRS to the effect that, among other things, the spin-off will qualify as a transaction that is tax-free for U.S. federal income tax purposes under Section 355 and 368(a)(1)(D) of the Internal Revenue Code continuing in effect. Harvard Bioscience has also received an opinion from its outside tax advisor to such effect. In connection with the ruling and the opinion, Harvard Bioscience made certain representations regarding it and its business. The Company has agreed that it will not take or fail to take any action which prevents or could reasonably be expected to prevent the tax-free status of the spin-off. HART has agreed to certain restrictions that are intended to preserve the tax-free status of the contribution and the Distribution. HART may take certain actions otherwise prohibited by these covenants if Harvard Bioscience receives a private letter ruling from the IRS or if HART obtains, and provides to Harvard Bioscience, an opinion from a U.S. tax counsel or accountant of recognized national standing, in either case, acceptable to Harvard Bioscience in its sole and absolute discretion to the effect that such action would not jeopardize the tax-free status of the contribution and the Distribution. These covenants include restrictions on HART's:

• issuance or sale of stock or other securities (including securities convertible into HART's stock but excluding certain compensatory arrangements);

• sales of assets outside the ordinary course of business; and

• entering into any other corporate transaction which would cause HART to undergo a 50% or greater change in HART's stock ownership.

In addition, current U.S. federal income tax law creates a presumption that the spin-off of HART would be taxable to the Company, but not its stockholders, if such spin-off is part of a “plan or series of related transactions” pursuant to which one or more persons acquire directly or indirectly stock representing a 50% or greater interest (by vote or value) in the Company or HART. Acquisitions that occur during the four-year period that begins two years before the date of the spin-off are presumed to occur pursuant to a plan or series of related transactions, unless it is established that the acquisition is not pursuant to a plan or series of transactions that includes the spin-off. U.S. Treasury regulations currently in effect generally provide that whether an acquisition and a spin-off are part of a plan is determined based on all of the facts and circumstances, including, but not limited to, specific factors described in the U.S. Treasury regulations. In addition, the U.S. Treasury regulations provide several “safe harbors” for acquisitions that are not considered to be part of a plan. These rules will limit the Company's ability during the two-year period following the spin-off to enter into certain transactions that may be advantageous to the Company and its stockholders, particularly issuing equity securities to satisfy financing needs, repurchasing equity securities, disposing of certain assets, engaging in mergers and acquisitions, and, under certain circumstances, acquiring businesses or assets with equity securities or agreeing to be acquired.

The following table sets forth the impact of discontinued operations on the Company's consolidated statements of income for the three and six months ended June 30, 2014 and 2013.

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)				(in thousands)
Gain on disposal of discontinued operations, UBI	$	-	$	139	$	-	$	339
(Loss) from discontinued operations, HART		-		(1,518)		-		(3,001)
Income tax (benefit)		-		(1,097)		-		(1,545)
(Loss) from discontinued operations, net of tax	$	-	$	(282)	$	-	$	(1,117)

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Related Party Transactions

6 Months Ended

Jun. 30, 2014

9. Related Party Transactions

In connection with the HART spin-off, the Company entered into various commercial agreements with HART. These agreements include: (i) a Separation and Distribution Agreement to effect the separation and spin-off distribution and provide other agreements to govern the Company's relationship with HART after the spin-off; (ii) an Intellectual Property Matters Agreement, which governs various intellectual property related arrangements between the Company and HART, including the separation of intellectual property rights between the Company and HART, as well as certain related cross-licenses between the two companies; (iii) a Product Distribution Agreement, which provides that each company will become the exclusive distributor for the other party for products such other party develops for sale in the markets served by the other; (iv) a Tax Sharing Agreement, which governs the Company's and HART's respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes for periods before, during and after the spin-off; and (v) a Transition Services Agreement, which provides for certain services to be performed on a transitional basis by the Company to facilitate HART's transition into a separate public reporting company. As part of the Transition Services Agreement, and for one year following the spin-off date, the Company will provide certain support services to HART, including, among others, accounting, payroll, human resources and information technology services, with the charges for the transition services generally intended to allow the Company to fully recover the costs directly associated with providing the services, plus all out-of-pocket costs and expenses.

The Company recorded revenues of approximately $31,000 and $109,000 for the three and six months ended June 30, 2014, respectively, as a result of the exclusive distribution rights pursuant to the Product Distribution Agreement. The Company's operating expenses were reduced by $41,000 and $101,000 for the three and six months ended June 30, 2014, respectively, as a result of the fees the Company charged to HART for services provided pursuant to the Transition Services Agreement. In addition, the Company's rent expense was reduced by $41,000 and $81,000 for the three and six months ended June 30, 2014, respectively, as a result of sublease rent charged to HART pursuant to a sublease between the two companies.

David Green, who is currently a Director of the Company and was also formerly the Company's President and interim CEO, is currently the Chairman and CEO of HART.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Warranties

6 Months Ended

Jun. 30, 2014

Warranties Disclosure [Abstract]

Warranties Disclosure [Text Block]

10. Warranties

Warranties are estimated and accrued at the time revenues are recorded. A rollforward of product warranties is as follows:

		Beginning				Ending
		Balance	Payments	Additions		Balance
		(in thousands)

Year ended December 31, 2013	$	222	(179)	262	$	305

Six Months Ended June 30, 2014	$	305	(51)	24	$	278

Employee Benefit Plans

6 Months Ended

Jun. 30, 2014

Employee Benefit Plans Disclosure [Abstract]

Employee Benefit Plans Disclosure [Text Block]

11. Employee Benefit Plans

Certain of the Company's subsidiaries in the United Kingdom, or UK, Harvard Apparatus Limited and Biochrom Limited, maintain contributory, defined benefit or defined contribution pension plans for substantially all of their employees. As of June 30, 2014, these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The components of the Company's defined benefit pension expense were as follows:

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)
Components of net periodic benefit cost:
Service cost	$	(8)	$	77	$	-	$	151
Interest cost		227		190		448		374
Expected return on plan assets		(167)		(125)		(330)		(246)
Net amortization loss		46		59		91		116
Net periodic benefit cost	$	98	$	201	$	209	$	395

For the three and six months ended June 30, 2014, the Company contributed $0.2 million and $0.4 million, respectively, to its defined benefit pension plans. For the three and six months ended June 30, 2013, the Company contributed $0.2 million and $0.5 million, respectively, to its defined benefit pension plans. The Company expects to contribute approximately $0.4 million to its defined benefit pension plans during the remainder of 2014.

During the three months ended June 30, 2014 the Company wrote down its Level 3 investment in a longevity fund by an additional $0.6 million, which reduced its value to $0. The impact on accumulated other comprehensive loss was $0.5 million, net of tax. The longevity fund invests in a portfolio of physical life insurance settlements that had been historically valued using the net asset values provided by the fund. Since June 2011, the fund has been closed to all activity. The write down during three months ended June 30, 2014 was due, in part, to communication from the longevity fund regarding its continued illiquidity and inactivity.

As of June 30, 2014 and December 31, 2013, the Company had an underfunded pension liability of approximately $5.6 million and $4.9 million, respectively, included in the other liabilities – non-current line item in the consolidated balance sheets.

Leases

6 Months Ended

Jun. 30, 2014

Leases Disclosure [Abstract]

Leases Disclosure [Text Block]

12. Leases

Rent expense was $0.4 million and $0.8 million for the three and six months ended June 30, 2014, respectively. Rent expense was $0.3 million and $0.6 million for the three and six months ended June 30, 2013, respectively.

During the three months ended June 30, 2014, the Company entered into Amendment No. 3 (the “Third Amendment”) amending the terms of the lease on the Company's corporate headquarters in Holliston, MA. The Third Amendment extended the term of the lease through August 31, 2024, while also expanding the Company's rentable square feet in the building by approximately 22,000 square feet to a total of approximately 83,000 square feet. The commencement date of the Third Amendment is approximately September 1, 2014.

Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at June 30, 2014, are as follows:

		Operating
		Leases
		(in thousands)
2015	$	1,824
2016		1,305
2017		1,322
2018		1,304
2019		1,182
Thereafter		4,973
Net minimum lease payments	$	11,910

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

Capital Stock

6 Months Ended

Jun. 30, 2014

Capital Stock Disclosure [Abstract]

Capital Stock Disclosure [Text Block]

13. Capital Stock

Common Stock

On February 5, 2008, the Company's Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company's common stock to shareholders of record as of the close of business on February 6, 2008. Initially, these rights will not be exercisable and will trade with the shares of the Company's common stock. Under the Shareholder Rights Plan, the rights generally will become exercisable if a person becomes an “acquiring person” by acquiring 20% or more of the common stock of the Company or if a person commences a tender offer that could result in that person owning 20% or more of the common stock of the Company. If a person becomes an acquiring person, each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of preferred stock which are equivalent to shares of the Company's common stock having a value of twice the exercise price of the right. If the Company is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock having a value of twice the exercise price of the right.

Preferred Stock

The Company's Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of June 30, 2014, the Company had no preferred stock issued or outstanding.

Employee Stock Purchase Plan (as amended, the “ESPP”)

In 2000, the Company approved the ESPP. Under this ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company's common stock. At the conclusion of the period, participating employees can purchase shares of the Company's common stock at 85% of the lower of the fair market value of the Company's common stock at the beginning or end of the period. Shares are issued under the ESPP for the six-month periods ending June 30 and December 31. Under this plan, 750,000 shares of common stock are authorized for issuance of which 558,456 shares were issued as of June 30, 2014. During the three months ended June 30, 2014, the Company issued 31,116 shares of the Company's common stock under the ESPP. During the three months ended June 30, 2013, the Company issued 27,305 shares of the Company's common stock under the ESPP.

Stock-Based Payment Awards

The Company accounts for stock-based payment awards in accordance with the provisions of ASC 718, Compensation – Stock Compensation, which requires that compensation expense is recognized for all stock-based payment awards made to employees and directors including stock options, restricted stock units and employee stock purchases related to the ESPP.

Stock option and restricted stock unit activity under the Company's Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “2000 Plan”) for the six months ended June 30, 2014 was as follows:

		Stock Options			Restricted Stock Units
				Weighted
		Stock		Average	Restricted
		Options		Exercise	Stock Units		Grant Date
		Outstanding		Price	Outstanding		Fair Value

Balance at December 31, 2013		6,690,845	$	3.42	463,973	$	4.32
	Granted	974,500		4.13	116,400		4.12
	Exercised	(395,060)		3.13	-		-
	Vested (RSUs)	-		-	(233,098)		-
	Cancelled / forfeited	(759,652)		4.78	(40,878)		4.36
Balance at June 30, 2014		6,510,633	$	3.38	306,397	$	4.30

The weighted average fair value of the options granted under the 2000 Plan during the three months ended June 30, 2014 and 2013 was $2.20 and $2.64, respectively, using the Black Scholes option-pricing model. The weighted average fair value of the options granted under the 2000 Plan during the six months ended June 30, 2014 and 2013 was $2.19 and $2.64, respectively. The following assumptions were used to estimate the fair value of stock options granted during the three and six months ended June 30, 2014 and 2013:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Volatility	57.16	%	57.20	%	56.83	%	57.20	%
Risk-free interest rate	1.80	%	1.18	%	1.78	%	1.18	%
Expected holding period (in years)	5.79		5.64		5.75		5.64
Dividend Yield	0.00	%	0.00	%	0.00	%	0.00	%

The Company used historical volatility to calculate the expected volatility as of June 30, 2014. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company's stock options. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years.

Stock-based compensation expense related to stock options, restricted stock units and the ESPP for the three and six months ended June 30, 2014 and 2013 was allocated as follows:

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)

Cost of product revenues	$	30	$	40	$	58	$	52
Sales and marketing		74		42		144		83
General and administrative		356		477		697		1,053
Research and development		12		10		20		17
Discontinued operations		-		19		-		32
Total stock-based compensation	$	472	$	588	$	919	$	1,237

The Company did not capitalize any stock-based compensation.

Earnings per share

Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options and restricted stock units into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2014	2013	2014	2013

Basic	32,045,314	30,102,691	31,946,654	29,941,294
Effect of assumed conversion of employee and director stock options and restricted stock units	900,618	1,592,547	988,801	1,738,970
Diluted	32,945,932	31,695,238	32,935,455	31,680,264

Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 2,477,884 and 2,724,220 shares of common stock for the three months ended June 30, 2014 and 2013, respectively, as the impact of these shares would be anti-dilutive. Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 2,578,743 and 2,464,906 shares of common stock for the six months ended June 30, 2014 and 2013, respectively, as the impact of these shares would be anti-dilutive.

Long Term Debt

6 Months Ended

Jun. 30, 2014

Long Term Debt Disclosure [Abstract]

Long Term Debt Disclosure [Text Block]

14. Long Term Debt

On August 7, 2009, the Company entered into an amended and restated $20.0 million revolving credit loan agreement with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders (the “2009 Credit Agreement”). On September 30, 2011, the Company entered into the First Amendment to the Amended and Restated Revolving Credit Loan Agreement (the “First Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The First Amendment extended the maturity date of the credit facility to August 7, 2013 and reduced the interest rate to the London Interbank Offered Rate plus 3.0%. On October 4, 2012, the Company entered into the Second Amendment to the Amended and Restated Revolving Credit Loan Agreement (the “Second Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The Second Amendment extended the maturity date of the credit facility to August 7, 2014.

On March 29, 2013, the Company entered into a Second Amended and Restated Revolving Credit Agreement (the “Credit Agreement”) with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders, that amended and restated the 2009 Credit Agreement. The Credit Agreement converted the Company's existing outstanding revolving advances into a term loan in the principal amount of $15.0 million (the “Term Loan”), provides a revolving credit facility in the maximum principal amount of $25.0 million (“Revolving Line”) and provides a delayed draw term loan of up to $15.0 million (the “DDTL”) to fund capital contributions to the Company's former subsidiary, HART. The maximum amount available under the Credit Agreement is $50.0 million as borrowings against the DDTL in excess of $10.0 million results in a dollar for dollar reduction in the Revolving Line capacity. The Revolving Line has a maturity date of March 29, 2016, while the Term Loan and DDTL have a maturity date of March 29, 2018.

On October 31, 2013, the Company amended the Credit Agreement to reduce the DDTL from up to $15.0 million to up to $10.0 million and allow for an additional $5.0 million to be available for drawing as advances under the Revolving Line.

Borrowings under the Term Loan and the DDTL shall bear interest at a rate based on either the effective London Interbank Offered Rate (LIBOR) for certain interest periods selected by the Company, or a daily floating rate based on the British Bankers' Association (BBA) LIBOR as published by Reuters (or other commercially available source providing quotations of BBA LIBOR), plus in either case, a margin of 3.0%. The Revolving Line shall bear interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR, plus in either case, a margin of 2.5%. The Company was required to fix the rate of interest on at least 50% of the Term Loan and the DDTL through the purchase of interest rate swaps. The Term Loan and DDTL each have interest payments due at the end of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowings, and principal payments due quarterly. The Revolving Line has interest payments due at the end of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowings.

The loans evidenced by the Credit Agreement, or the Loans, are guaranteed by all of the Company's direct and indirect domestic subsidiaries, and secured by substantially all of the assets of the Company and the guarantors. The Loans are subject to restrictive covenants under the Credit Agreement, and financial covenants that require the Company and its subsidiaries to maintain certain financial ratios on a consolidated basis, including a maximum leverage, minimum fixed charge coverage and minimum working capital. Prepayment of the Loans is allowed by the Credit Agreement at any time during the terms of the Loans. The Loans also contain limitations on the Company's ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of $6.0 million and for acquisitions funded solely with equity in excess of $10.0 million.

As of June 30, 2014 and December 31, 2013, the Company had borrowings of $22.3 million and $24.8 million, respectively, outstanding under its Credit Agreement. As of June 30, 2014, the Company was in compliance with all financial covenants contained in the Credit Agreement, was subject to a working capital borrowing restriction and had available borrowing capacity under its Credit Agreement of $21.6 million.

As of June 30, 2014, the weighted effective interest rates on the Company's Term Loan, DDTL and Revolving Line borrowings were 3.96%, 3.54% and 3.15%, respectively.

As of June 30, 2014 and December 31, 2013, the Company's borrowings were comprised of:

		June 30,		December 31,
		2014		2013
		(in thousands)
Long-term debt:
Term loan	$	11,250	$	12,750
DDTL		8,500		9,500
Revolving line		2,500		2,500
Total debt		22,250		24,750
Less: current installments		(5,000)		(5,000)
Long-term debt	$	17,250	$	19,750

Derivatives

6 Months Ended

Jun. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

15. Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty's credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company's outstanding or forecasted debt obligations as well as the Company's offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company's future cash flows.

The Company uses variable-rate London Interbank Offered Rate (LIBOR) debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. In accordance with its Credit Agreement, the Company was required to fix the rate of interest on at least 50% of its Term Loan and the DDTL through the purchase of interest rate swaps. On June 5, 2013, the Company entered into an interest rate swap contract with an original notional amount of $15.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company's Term Loan. On November 29, 2013, the Company entered into a second interest rate swap contract with an original notional amount of $5.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the DDTL. The Term Loan swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.96% plus a bank margin of 3.0%. The DDTL swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.93% plus a bank margin of 3.0%.The interest rate swaps were designated as cash flow hedges in accordance with ASC 815, Derivatives and Hedging.

The following table presents the notional amount and fair value of the Company's derivative instruments as of June 30, 2014 and December 31, 2013.


				June 30, 2014		June 30, 2014
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swap		Other liabilities-non current	$	15,500	$	(60)


				December 31, 2013		December 31, 2013
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swap		Other liabilities-non current	$	17,500	$	(49)

	(a) See note 16 for the fair value measurements related to these financial instruments.

All of the Company's derivative instruments are designated as hedging instruments.

The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (“AOCI”). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company's interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive income for the three and six months ended June 30, 2014 and 2013:

Derivatives in Hedging Relationships	Amount of gain or (loss) recognized in OCI on derivative (effective portion)
	Three months ended				Six months ended
	June 30,				June 30,
	2014		2013		2014		2013
	(in thousands)
Interest rate swap	$	(56)	$	(53)	$	(80)	$	(53)

The following table summarizes the reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended June 30, 2014 and 2013:

Details about AOCI Components	Amount of gain or (loss) reclassified from AOCI into income (effective portion)								Location of gain or (loss)
	Three months ended				Six months ended				reclassified from AOCI
	June 30,				June 30,				into income (effective portion)
	2014		2013		2014		2013
	(in thousands)
Interest rate swap	$	(34)	$	(7)	$	(69)	$	(7)	Interest expense

As of June 30, 2014, $0.1 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives' losses to earnings include the repricing of variable-rate debt. There were no cash flow hedges discontinued during 2014 or 2013.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurements

6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

16. Fair Value Measurements

Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company's own assumptions.

The following tables present the fair value hierarchy for those liabilities measured at fair value on a recurring basis:

	Fair Value as of June 30, 2014
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	60	$	-	$	60


	Fair Value as of December 31, 2013
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	49	$	-	$	49

The Company uses the market approach technique to value its financial liabilities. The Company's financial liabilities carried at fair value include derivative instruments used to hedge the Company's interest rate risks. The fair value of the Company's interest rate swap agreements was based on LIBOR yield curves at the reporting date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

6 Months Ended

Jun. 30, 2014

Income Tax [Abstract]

Income Taxes Disclosure [Text Block]

17. Income Tax

The effective income tax rate for continuing operations was 19.5% and 77.0% for the three months ended June 30, 2014 and 2013, respectively. The difference between the effective tax rate quarter over quarter was primarily attributable to higher research and development tax credits in 2013 versus 2014 due, in part, to the expiration of the U.S. research credit at the end of 2013, offset by discrete expense items related to certain non-deductible costs in 2013.

The effective income tax rate for continuing operations was 23.9% and 37.7% for the six months ended June 30, 2014 and 2013, respectively. The difference between the effective tax rate year over year was primarily attributable to higher research and development tax credits in 2013 versus 2014 due, in part, to the expiration of the U.S. research credit at the end of 2013, offset by discrete expense items related to certain non-deductible costs in 2013.

Subsequent Events

6 Months Ended

Jun. 30, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

18. Subsequent Events

On July 30, 2014, the Company entered into amendments to its Employment Agreements with Jeffrey A. Duchemin, its Chief Executive Officer, and Robert E. Gagnon, its Chief Financial Officer (the “Amendments”). The Amendments extended the term of each Employment Agreement through August 26, 2016 and increased the renewal periods from one to two years under each agreement.

As part of Mr. Duchemin's Amendment, the vesting terms of his option grants were modified such that upon termination of his Employment Agreement by the Company without cause or by Mr. Duchemin with good reason, all options that would vest within twelve months, and twenty four months with respect to his inducement grant, following the termination date will accelerate and become fully vested. This modification of the vesting terms has no financial impact on the Company's reported financial position or operations.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2014
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. This standard will be effective as of the beginning of the Company's 2017 fiscal year. The Company is assessing the new standard and has not yet determined the impact to the consolidated financial statements.
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation [Policy Text Block]	HARVARD BIOSCIENCE, INC. Notes to Unaudited Consolidated Financial Statements 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of June 30, 2014 and for the three and six months ended June 30, 2014 and 2013 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2013 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 14, 2014. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2014, results of operations and comprehensive income (loss) for the three and six months ended June 30, 2014 and 2013 and cash flows for the six months ended June 30, 2014 and 2013, as applicable, have been made. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 14, 2014.

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References + Details

Accumulated Other Comprehensive Income (Tables)

6 Months Ended

Jun. 30, 2014

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income [Table Text Block]

		Foreign currency		Derivatives
		translation		qualifying as		Defined benefit
(in thousands)		adjustments		hedges		pension plans		Total

Balance at December 31, 2013	$	1,283	$	(49)	$	(3,878)	$	(2,644)

Other comprehensive income (loss) before reclassifications		584		(80)		(484)		20
Amounts reclassified from AOCI		-		69		-		69

Net other comprehensive income		584		(11)		(484)		89

Balance at June 30, 2014	$	1,867	$	(60)	$	(4,362)	$	(2,555)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Details about AOCI Components	Amount of gain or (loss) reclassified from AOCI into income (effective portion)								Location of gain or (loss)
	Three months ended				Six months ended				reclassified from AOCI
	June 30,				June 30,				into income (effective portion)
	2014		2013		2014		2013
	(in thousands)
Interest rate swap	$	(34)	$	(7)	$	(69)	$	(7)	Interest expense

Goodwill and Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2014

Goodwill And Other Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

									Weighted
									Average
		June 30, 2014				December 31, 2013			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	13,581	$	(11,480)	$	13,464	$	(11,091)	3.9	Years
Trade names		6,141		(2,374)		6,178		(2,185)	10.5	Years
Distribution agreement/customer relationships		21,713		(10,155)		21,827		(9,447)	10.2	Years
Patents		280		(27)		271		(8)	4.7	Years
Total amortizable intangible assets		41,715	$	(24,036)		41,740	$	(22,731)

Indefinite-lived intangible assets:
Goodwill		36,839				36,605
Other indefinite-lived intangible assets		1,287				1,289
Total goodwill and other indefinite-lived intangible assets		38,126				37,894

Total intangible assets	$	79,841			$	79,634

(a) Weighted average life as of June 30, 2014.

Goodwill Rollforward [Table Text Block]

			(in thousands)
Balance at December 31, 2013		$	36,605
	Effect of change in foreign currencies		234
Balance at June 30, 2014		$	36,839

Inventories (Tables)

6 Months Ended

Jun. 30, 2014

Inventories Disclosure [Abstract]

Schedule of Inventory [Table Text Block]

			June 30,		December 31,
			2014		2013
			(in thousands)
Finished goods		$	8,396	$	7,039
Work in process			663		752
Raw materials			8,152		7,986
	Total	$	17,211	$	15,777

Property, Plant and Equipment (Tables)

6 Months Ended

Jun. 30, 2014

Property, Plant and Equipment Disclosure [Abstract]

Schedule Of Property Plant And Equipment [Table Text Block]

		June 30,		December 31,
		2014		2013
		(in thousands)
Land, buildings and leasehold improvements	$	2,446	$	3,082
Machinery and equipment		9,994		9,471
Computer equipment and software		5,298		4,927
Furniture and fixtures		1,336		1,281
Automobiles		59		59
		19,133		18,820
Less: accumulated depreciation		(15,005)		(14,445)
Property, plant and equipment, net	$	4,128	$	4,375

Restructuring and Other Exit Costs (Tables)

6 Months Ended

Jun. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring Plan Table [Table Text Block]

		Severance and
		Related Costs		Other		Total
		(in thousands)
Restructuring charges - 2013	$	2,100	$	-	$	2,100
Cash payments		(666)		-		(666)
Restructuring balance at December 31, 2013		1,434		-		1,434
Restructuring charges		195		175		370
Non-cash reversal of restructuring charges		(115)		-		(115)
Cash payments		(1,184)		(159)		(1,343)
Restructuring balance at June 30, 2014	$	330	$	16	$	346

		Severance
		and Related Costs		Other		Total
		(in thousands)
Restructuring charges	$	312	$	11	$	323
Cash payments		(179)		-		(179)
Restructuring balance at December 31, 2012		133		11		144
Cash payments		(84)		(11)		(95)
Non-cash reversal of restructuring charges		(46)		-		(46)
Restructuring balance at December 31, 2013		3		-		3
Non-cash reversal of restructuring charges		(3)		-		(3)
Restructuring balance at June 30, 2014	$	-	$	-	$	-

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)				(in thousands)
Restructuring charges (credits)	$	115	$	(24)	$	252	$	(45)

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2014

Discontinued Operations [Abstract]

Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Table Text Block]

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)				(in thousands)
Gain on disposal of discontinued operations, UBI	$	-	$	139	$	-	$	339
(Loss) from discontinued operations, HART		-		(1,518)		-		(3,001)
Income tax (benefit)		-		(1,097)		-		(1,545)
(Loss) from discontinued operations, net of tax	$	-	$	(282)	$	-	$	(1,117)

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References + Details

Warranties (Tables)

6 Months Ended

Jun. 30, 2014

Warranties Disclosure [Abstract]

Warranty Rollforward Disclosure [Table Text Block]

		Beginning				Ending
		Balance	Payments	Additions		Balance
		(in thousands)

Year ended December 31, 2013	$	222	(179)	262	$	305

Six Months Ended June 30, 2014	$	305	(51)	24	$	278

Employee Benefit Plans (Tables)

6 Months Ended

Jun. 30, 2014

Employee Benefit Plans Disclosure [Abstract]

Schedule Of Costs Of Retirement Plans [Table Text Block]

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)
Components of net periodic benefit cost:
Service cost	$	(8)	$	77	$	-	$	151
Interest cost		227		190		448		374
Expected return on plan assets		(167)		(125)		(330)		(246)
Net amortization loss		46		59		91		116
Net periodic benefit cost	$	98	$	201	$	209	$	395

Leases (Tables)

6 Months Ended

Jun. 30, 2014

Leases Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

		Operating
		Leases
		(in thousands)
2015	$	1,824
2016		1,305
2017		1,322
2018		1,304
2019		1,182
Thereafter		4,973
Net minimum lease payments	$	11,910

Capital Stock (Tables)

6 Months Ended

Jun. 30, 2014

Capital Stock Disclosure [Abstract]

Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]

		Stock Options			Restricted Stock Units
				Weighted
		Stock		Average	Restricted
		Options		Exercise	Stock Units		Grant Date
		Outstanding		Price	Outstanding		Fair Value

Balance at December 31, 2013		6,690,845	$	3.42	463,973	$	4.32
	Granted	974,500		4.13	116,400		4.12
	Exercised	(395,060)		3.13	-		-
	Vested (RSUs)	-		-	(233,098)		-
	Cancelled / forfeited	(759,652)		4.78	(40,878)		4.36
Balance at June 30, 2014		6,510,633	$	3.38	306,397	$	4.30

Table Of Assumptions [Table Text Block]

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Volatility	57.16	%	57.20	%	56.83	%	57.20	%
Risk-free interest rate	1.80	%	1.18	%	1.78	%	1.18	%
Expected holding period (in years)	5.79		5.64		5.75		5.64
Dividend Yield	0.00	%	0.00	%	0.00	%	0.00	%

Stock Based Compensation Expense Activity By Function [Table Text Block]

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)

Cost of product revenues	$	30	$	40	$	58	$	52
Sales and marketing		74		42		144		83
General and administrative		356		477		697		1,053
Research and development		12		10		20		17
Discontinued operations		-		19		-		32
Total stock-based compensation	$	472	$	588	$	919	$	1,237

Basic and Diluted Shares [Table Text Block]

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2014	2013	2014	2013

Basic	32,045,314	30,102,691	31,946,654	29,941,294
Effect of assumed conversion of employee and director stock options and restricted stock units	900,618	1,592,547	988,801	1,738,970
Diluted	32,945,932	31,695,238	32,935,455	31,680,264

Long Term Debt (Tables)

6 Months Ended

Jun. 30, 2014

Long Term Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

		June 30,		December 31,
		2014		2013
		(in thousands)
Long-term debt:
Term loan	$	11,250	$	12,750
DDTL		8,500		9,500
Revolving line		2,500		2,500
Total debt		22,250		24,750
Less: current installments		(5,000)		(5,000)
Long-term debt	$	17,250	$	19,750

Derivative (Tables)

6 Months Ended

Jun. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]


				June 30, 2014		June 30, 2014
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swap		Other liabilities-non current	$	15,500	$	(60)


				December 31, 2013		December 31, 2013
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swap		Other liabilities-non current	$	17,500	$	(49)

	(a) See note 16 for the fair value measurements related to these financial instruments.

Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]

Derivatives in Hedging Relationships	Amount of gain or (loss) recognized in OCI on derivative (effective portion)
	Three months ended				Six months ended
	June 30,				June 30,
	2014		2013		2014		2013
	(in thousands)
Interest rate swap	$	(56)	$	(53)	$	(80)	$	(53)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Details about AOCI Components	Amount of gain or (loss) reclassified from AOCI into income (effective portion)								Location of gain or (loss)
	Three months ended				Six months ended				reclassified from AOCI
	June 30,				June 30,				into income (effective portion)
	2014		2013		2014		2013
	(in thousands)
Interest rate swap	$	(34)	$	(7)	$	(69)	$	(7)	Interest expense

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]

	Fair Value as of June 30, 2014
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	60	$	-	$	60


	Fair Value as of December 31, 2013
(In thousands)		Level 1		Level 2		Level 3		Total
Liabilities:
Interest rate swap agreements	$	-	$	49	$	-	$	49

Summary of Significant Accounting Policy (Details 1)

6 Months Ended

Jun. 30, 2014

^[1]

Developed Technology Rights [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Weighted Average Useful Life

3 years 10 months 24 days

Trade Names [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Weighted Average Useful Life

10 years 6 months

Customer Relationships [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Weighted Average Useful Life

10 years 2 months 12 days

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Weighted Average Useful Life

4 years 8 months 12 days

[1]	(a) Weighted average life as of June 30, 2014.

Accumulated Other Comprehensive Income (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2014 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	$ (2,644)
Other Comprehensive Income (Loss) before Reclassifications	20
Reclassification from Accumulated Other Comprehensive Income	69
Other Comprehensive Income (Loss), Net of Tax	89
Closing Balance	(2,555)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	1,283
Other Comprehensive Income (Loss) before Reclassifications	584
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax	584
Closing Balance	1,867
Derivatives qualifying as hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(49)
Other Comprehensive Income (Loss) before Reclassifications	(80)
Reclassification from Accumulated Other Comprehensive Income	69
Other Comprehensive Income (Loss), Net of Tax	(11)
Closing Balance	(60)
Defined benefit pension plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(3,878)
Other Comprehensive Income (Loss) before Reclassifications	(484)
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax	(484)
Closing Balance	$ (4,362)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 587	$ 676	$ 1,221	$ 1,355
Estimated 2014 Amortization Expense	2,500		2,500
Estimated 2015 Amortization Expense	2,200		2,200
Estimated 2016 Amortization Expense	2,100		2,100
Estimated 2017 Amortization Expense	1,800		1,800
Estimated 2018 Amortization Expense	$ 1,700		$ 1,700

Goodwill and Other Intangible Assets (Details 1) - USD ($)
$ in Thousands

6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross

$ 41,715

$ 41,740

Finite-Lived Intangible Assets, Accumulated Amortization

(24,036)

(22,731)

Goodwill

36,839

36,605

Other indefinite lived intangible assets

1,287

1,289

Total goodwill and other indefinite lived intangible assets

38,126

37,894

Total intangible assets

79,841

79,634

Developed Technology Rights [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross

13,581

13,464

Finite-Lived Intangible Assets, Accumulated Amortization

$ (11,480)

(11,091)

Finite-Lived Intangible Assets, Weighted Average Useful Life

^[1]

3 years 10 months 24 days

Trade Names [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross

$ 6,141

6,178

Finite-Lived Intangible Assets, Accumulated Amortization

$ (2,374)

(2,185)

Finite-Lived Intangible Assets, Weighted Average Useful Life

^[1]

10 years 6 months

Customer Relationships [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross

$ 21,713

21,827

Finite-Lived Intangible Assets, Accumulated Amortization

$ (10,155)

(9,447)

Finite-Lived Intangible Assets, Weighted Average Useful Life

^[1]

10 years 2 months 12 days

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross

$ 280

271

Finite-Lived Intangible Assets, Accumulated Amortization

$ (27)

$ (8)

Finite-Lived Intangible Assets, Weighted Average Useful Life

^[1]

4 years 8 months 12 days

[1]	(a) Weighted average life as of June 30, 2014.

Goodwill and Other Intangible Assets (Details 2) $ in Thousands	6 Months Ended
	Jun. 30, 2014 USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 36,605
Acquired during the period	0
Foreign currency translation adjustments related to goodwill balance	234
Goodwill, Ending Balance	$ 36,839

Inventories (Details 1) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Inventories Disclosure [Abstract]
Finished Goods	$ 8,396	$ 7,039
Work in Process	663	752
Raw Materials	8,152	7,986
Total Inventories, Net	$ 17,211	$ 15,777

Property, Plant and Equipment (Details 1) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 19,133	$ 18,820
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,005)	(14,445)
Property, plant and equipment, net	4,128	4,375
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,446	3,082
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,994	9,471
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	5,298	4,927
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,336	1,281
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 59	$ 59

Restructuring and Other Exit Cots (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)	$ 115	$ (24)	$ 252	$ (45)
Restructuring Plan 2012 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)						$ 323
Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)			370		$ 2,100
Restructuring number of positions eliminated, percent					13.00%
Employee Severance [Member] \| Restructuring Plan 2012 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)						312
Employee Severance [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)			195		$ 2,100
Other Costs [Member] \| Restructuring Plan 2012 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)						$ 11
Other Costs [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)			$ 175		$ 0

Restructuring and Other Exit Costs (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)	$ 115	$ (24)	$ 252	$ (45)
Restructuring Plan 2012 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			3	144	$ 144
Restructuring charges (credits)						$ 323
Restructuring Reserve, Settled with Cash					(95)	(179)
Restructuring Reserve, Accrual Adjustment			(3)		(46)
Restructuring Reserve, Ending Balance	0		0		3	144
Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			1,434
Restructuring charges (credits)			370		2,100
Restructuring Reserve, Settled with Cash			(1,343)		(666)
Restructuring Reserve, Accrual Adjustment			(115)
Restructuring Reserve, Ending Balance	346		346		1,434
Employee Severance [Member] \| Restructuring Plan 2012 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			3	133	133
Restructuring charges (credits)						312
Restructuring Reserve, Settled with Cash					(84)	(179)
Restructuring Reserve, Accrual Adjustment			(3)		(46)
Restructuring Reserve, Ending Balance	0		0		3	133
Employee Severance [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			1,434
Restructuring charges (credits)			195		2,100
Restructuring Reserve, Settled with Cash			(1,184)		(666)
Restructuring Reserve, Accrual Adjustment			(115)
Restructuring Reserve, Ending Balance	330		330		1,434
Other Costs [Member] \| Restructuring Plan 2012 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			0	$ 11	11
Restructuring charges (credits)						11
Restructuring Reserve, Settled with Cash					(11)	0
Restructuring Reserve, Accrual Adjustment			0		0
Restructuring Reserve, Ending Balance	0		0		0	$ 11
Other Costs [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			0
Restructuring charges (credits)			175		0
Restructuring Reserve, Settled with Cash			(159)		0
Restructuring Reserve, Accrual Adjustment			0
Restructuring Reserve, Ending Balance	$ 16		$ 16		$ 0

Discontinued Operations (Narratives) (Details) - USD ($) $ in Thousands, shares in Millions						3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 01, 2013	Oct. 31, 2013	Oct. 21, 2013	Jun. 28, 2013	Mar. 22, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from Discontinued Operations, Net of Tax, Attributable to Parent						$ 0	$ (282)	$ 0	$ (1,117)
Assets transferred as part of HART spin-off	$ 900
Transfer of cash and cash equivalents to HART	$ (15,000)
Date of Separation Plan Completed	November 1, 2013
Dividends Payable Date Of Record Day Month And Year			Oct. 21, 2013
Spin-off distribution ratio spinnee to spinnor	1 for 4
Date Entered Into Commerical Agreements With Spinnee		31-Oct-13
Lost Value Adjustment Maintained To Share And Exercise Price Of Existing Options	80.00%
Percent Lost Value Provided Back To Option Holder	20.00%
Lost Value Adjustment To Share Amount Of Existing Outstanding Restricted Stock Units	80.00%
Percent Lost Value Provided Back To Restricted Stock Unit Holder	20.00%
Options Granted due to the Spin-off of HART	1.7
Restricted Stock Units Granted due to the Spin-off of HART	0.1
Date of Private Letter Ruling					22-Mar-13
Date of Supplemental Ruling to Private Letter Ruling				28-Jun-13
Percent of Acquired Stock to Create Taxable Spin-off	50.00%
Union Biometrica Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from Discontinued Operations, Net of Tax, Attributable to Parent						0	139	0	339
Proceeds from sale of discontinued operations										$ 1,800
Harvard Apparatus Regnerative Technology [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from Discontinued Operations, Net of Tax, Attributable to Parent						0	(1,518)	0	(3,001)
Income Taxes [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from Discontinued Operations, Net of Tax, Attributable to Parent						$ 0	$ (1,097)	$ 0	$ (1,545)

Related Party Transactions (Narratives) (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Related Party Transactions [Abstract]
HART Sublease Rent	$ 41,000	$ 81,000
Transition Services Charged to HART	41,000	101,000
Distribution Revenues From Spinnee	$ 31,000	$ 109,000

Warranties (Details 1) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Warranties (Details 1) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 305	$ 222
Warranty payments	(51)	(179)
Warranty additions	24	262
Warranty, Ending Balance	$ 278	$ 305

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year			$ 400
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	$ 200	400	$ 500
Defined Benefit Plans Liabilities Noncurrent	5,600		5,600		$ 4,900
Unrealized losses on pension benefit obligation, net of tax	$ 484	$ 0	$ 484	$ 0

Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Benefit Plans Disclosure [Abstract]
Service Cost	$ (8)	$ 77	$ 0	$ 151
Interest Cost	227	190	448	374
Expected Return on Plan Assets	(167)	(125)	(330)	(246)
Net Amortization Loss	46	59	91	116
Curtailment Gain	0	0	0	0
Net Periodic Benefit Cost, Total	98	201	209	395
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest Cost	227	190	448	374
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	$ 200	$ 400	$ 500

Employee Benefit Plans (Details 4) $ in Millions	6 Months Ended
Employee Benefit Plans (Details 4) $ in Millions	Jun. 30, 2014 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Unrealized Loss Gain	$ 0.6

Leases (Narratives) (Details) $ in Millions	3 Months Ended		6 Months Ended
Leases (Narratives) (Details) $ in Millions	Jun. 30, 2014 USD ($) ft²	Jun. 30, 2013 USD ($)	Jun. 30, 2014 USD ($) ft²	Jun. 30, 2013 USD ($)
Leases Disclosure [Abstract]
Operating Leases, Rent Expense, Net \| $	$ 0.4	$ 0.3	$ 0.8	$ 0.6
Square Footage of Real Estate Property	83,000		83,000
Lease Expiration Date			Aug. 31, 2024
Expansion Area Of Real Estate Property	22,000		22,000

Leases (Details 1) $ in Thousands	Jun. 30, 2014 USD ($)
Leases Disclosure [Abstract]
2015	$ 1,824
2016	1,305
2017	1,322
2018	1,304
2019	1,182
Thereafter	4,973
Operating Leases, Total Future Minimum Payments Due	$ 11,910

Capital Stock (Details 1) - $ / shares	3 Months Ended		6 Months Ended
Capital Stock (Details 1) - $ / shares	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Capital Stock Disclosure [Abstract]
Opening Balance Stock Options Outstanding			6,690,845
Begining Balance Weighted Average Exercise Price			$ 3.42
Options, Grants in Period, Gross			974,500
Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 4.13
Options, Forfeitures and Expirations in Period			(759,652)
Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price			$ 4.78
Closing Balance Stock Options Outstanding	6,510,633		6,510,633
Closing Balance Weighted Average Exercise Price	$ 3.38		$ 3.38
Begining Balance Restricted Stock Units Outstanding			463,973
Equity Instruments Other than Options, Grants in Period			116,400
Equity Instruments Other than Options, Vested in Period			(233,098)
Closing Balance Restricted Stock Units Outstanding	306,397		306,397
Begining Balance Grant Date Fair Value Of Restricted Stock Units			$ 4.32
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			4.12
Closing Balance Grant Date Fair Value Of Restricted Stock Units	$ 4.30		$ 4.30
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair Value Assumptions, Expected Volatility Rate	57.16%	57.20%	56.83%	57.20%
Fair Value Assumptions, Risk Free Interest Rate	1.80%	1.18%	1.78%	1.18%
Fair Value Assumptions, Expected Term	5 years 9 months 14 days	5 years 7 months 20 days	5 years 9 months	5 years 7 months 20 days
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Options, Exercises in Period, Weighted Average Exercise Price			$ 3.13
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value			$ 4.36
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			(40,878)
Preferred Stock - Shares Authorized	5,000,000		5,000,000		5,000,000
Stock Issued During Period Gross Stock Options Exercised			395,060

Capital Stock (Narratives) (Details) - $ / shares	3 Months Ended		6 Months Ended		174 Months Ended
Capital Stock (Narratives) (Details) - $ / shares	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013	Nov. 01, 2013
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Employee Stock Purchase Plan Shares Authorized	750,000		750,000		750,000
Stock issued during the year, Shares, Employee Stock Purchase Plans	31,116	27,305			558,456
Equity Instruments Other than Options, Grants in Period			116,400
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,477,884	2,724,220	2,578,743	2,464,906
Percentage Of Outstanding Common Stock	20.00%		20.00%		20.00%
Weighted Average Estimated Black Scholes Value Of Option Grants	$ 2.20	$ 2.64	$ 2.19	$ 2.64
Options Granted due to the Spin-off of HART							1,700,000
Restricted Stock Units Granted due to the Spin-off of HART							100,000
Preferred Stock - Shares Authorized	5,000,000		5,000,000		5,000,000	5,000,000

Capital Stock (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Capital Stock (Details 2) - USD ($) $ in Thousands	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 472	$ 588	$ 919	$ 1,237
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	32,045,314	30,102,691	31,946,654	29,941,294
Weighted Average Number Diluted Shares Outstanding Adjustment	900,618	1,592,547	988,801	1,738,970
Diluted	32,945,932	31,695,238	32,935,455	31,680,264
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 30	$ 40	$ 58	$ 52
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	12	10	20	17
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	74	42	144	83
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	356	477	697	1,053
Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 0	$ 19	$ 0	$ 32

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands				3 Months Ended
	Oct. 31, 2013	Mar. 29, 2013	Aug. 07, 2009	Jun. 30, 2014	Dec. 31, 2013
Credit Agreement [Line Items]
Previous Approved Credit Facility			$ 20,000
Secured Debt				$ 22,250	$ 24,750
Line of Credit Facility, Maximum Borrowing Capacity		$ 50,000
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on				50.00%
Line of Credit Facility, Remaining Borrowing Capacity				$ 21,600
Interest Rate In Excess Of LIBOR On Credit Facility			3.00%
DDTL Threshold For Dollar For Dollar Reduction In Revolving Line		10,000
Transfer Of Delayed Draw Down Term Loan Capacity To Revolver Capacity	$ 5,000
Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold				6,000
Lender Approval To Fund Acquisition With Equity In Excess Of Threshold				10,000
Revolving Credit Facility [Member]
Credit Agreement [Line Items]
Secured Debt		$ 25,000		$ 2,500	2,500
Maturity Dates		Mar. 29, 2016
Basis Spread Over LIBOR		2.50%
Interest Rate As Of Reporting Date				3.15%
Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt		$ 15,000		$ 11,250	12,750
Maturity Dates		Mar. 29, 2018
Basis Spread Over LIBOR		3.00%
Interest Rate As Of Reporting Date				3.96%
Delayed Drawdown Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt		$ 15,000		$ 8,500	$ 9,500
Maturity Dates		Mar. 29, 2018
Basis Spread Over LIBOR		3.00%
Maximum Borrowings Available Under The Current Credit Agreement	$ 10,000
Interest Rate As Of Reporting Date				3.54%

Long Term Debt (Details 1) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013	Mar. 29, 2013
Debt Instrument [Line Items]
Secured Debt	$ 22,250	$ 24,750
Current portion, long-term debt	(5,000)	(5,000)
Long-term debt	17,250	19,750
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Secured Debt	2,500	2,500	$ 25,000
Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	11,250	12,750	15,000
Delayed Drawdown Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	$ 8,500	$ 9,500	$ 15,000

Derivative (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended
Derivative (Narratives) (Details) - USD ($) $ in Thousands	Jun. 30, 2014	Nov. 30, 2013	Jun. 05, 2013
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on	50.00%
Notional Amount of Interest Rate Swaps	$ 15,500
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings	$ 100
Derivative Interest Rate Swap Effective Percentage	100.00%
Delayed Drawdown Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps		$ 5,000
LIBOR Fixed Rate	0.93%
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps			$ 15,000
LIBOR Fixed Rate	0.96%

Derivative (Details 1) - USD ($)
$ in Thousands

Jun. 30, 2014

Dec. 31, 2013

Derivatives, Fair Value [Line Items]

Notional Amount of Interest Rate Derivatives

$ 17,500

Derivative Liability, Fair Value, Net

$ (49)

Other liabilities-non current [Member] | Derivatives qualifying as hedges [Member]

Derivatives, Fair Value [Line Items]

Derivative Liability, Fair Value, Net

^[1]

$ (60)

[1]	(a) See note 16 for the fair value measurements related to these financial instruments.

Derivative (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Derivative (Details 2) - USD ($) $ in Thousands	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion	$ (56)	$ (53)	$ (80)	$ (53)
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	$ (34)	$ (7)	$ (69)	$ (7)

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 60	$ 49
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	60	49
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Income Tax (Narratives) (Details)	3 Months Ended		6 Months Ended
Income Tax (Narratives) (Details)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax [Abstract]
Effective Income Tax Rate	19.50%	77.00%	23.90%	37.70%